| Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy MG Riga, L Chelis, S Kakolyris, S Papadopoulos, S Stathakidou, ... American journal of clinical oncology 36 (1), 1-6, 2013 | 120 | 2013 |
| Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients I Balgkouranidou, D Matthaios, A Karayiannakis, H Bolanaki, P Michailidis, ... Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 778, 46-51, 2015 | 87 | 2015 |
| Methylation status of the APC and RASSF1A promoter in cell‑free circulating DNA and its prognostic role in patients with colorectal cancer D Matthaios, I Balgkouranidou, A Karayiannakis, H Bolanaki, N Xenidis, ... Oncology letters 12 (1), 748-756, 2016 | 58 | 2016 |
| Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? M Mantatzis, S Kakolyris, K Amarantidis, A Karayiannakis, ... European radiology 19, 1809-1816, 2009 | 54 | 2009 |
| Pancreatic cancer from molecular pathways to treatment opinion M Karanikas, A Esempidis, ZTM Chasan, T Deftereou, M Antonopoulou, ... Journal of Cancer 7 (10), 1328, 2016 | 52 | 2016 |
| Reversible posterior leukoencephalopathy syndrome induced by pazopanib L Chelis, V Souftas, K Amarantidis, N Xenidis, E Chamalidou, ... BMC cancer 12, 1-5, 2012 | 41 | 2012 |
| Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer K Amarantidis, N Xenidis, L Chelis, E Chamalidou, P Dimopoulos, ... Oncology 80 (5-6), 359-365, 2011 | 30 | 2011 |
| Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study S Kakolyris, N Ziras, L Vamvakas, J Varthalitis, P Papakotoulas, K Syrigos, ... Lung Cancer 54 (3), 347-352, 2006 | 26 | 2006 |
| Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study N Xenidis, L Chelis, K Amarantidis, E Chamalidou, P Dimopoulos, ... Cancer chemotherapy and pharmacology 69, 477-484, 2012 | 23 | 2012 |
| VEGF expression in the colorectal adenoma-carcinoma sequence L Kaklamanis, M Trichas, K Amarantidis, N Spathari, A Micheli, ... Oncology Research-Incorporating Anti-Cancer Drug Design 15 (9), 445, 2004 | 19 | 2004 |
| Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients EI Karamitrousis, I Balgkouranidou, N Xenidis, K Amarantidis, E Biziota, ... Technology in cancer research & treatment 20, 1533033820973279, 2021 | 15 | 2021 |
| Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study S Kakolyris, K Kalbakis, A Potamianou, N Malamos, L Vamvakas, ... Oncology 70 (4), 273-279, 2006 | 12 | 2006 |
| Methylation status of corticotropin-releasing factor (CRF) receptor genes in colorectal cancer M Panagopoulou, A Cheretaki, M Karaglani, I Balgkouranidou, E Biziota, ... Journal of Clinical Medicine 10 (12), 2680, 2021 | 10 | 2021 |
| Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial I Gioulbasanis, Z Saridaki, A Kalykaki, L Vamvakas, K Kalbakis, ... Anticancer research 28 (5B), 3019-3025, 2008 | 10 | 2008 |
| Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity C Ioannou, G Ragia, I Balgkouranidou, N Xenidis, K Amarantidis, ... Pharmacogenomics 22 (11), 669-680, 2021 | 9 | 2021 |
| Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan … S Kakolyris, J Souglakos, A Polyzos, A Ardavanis, N Ziras, A Athanasiadis, ... Oncology 74 (1-2), 31-36, 2008 | 7 | 2008 |
| MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements C Ioannou, G Ragia, I Balgkouranidou, N Xenidis, K Amarantidis, ... Drug Metabolism and Personalized Therapy 37 (3), 323-327, 2022 | 6 | 2022 |
| Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer N Xenidis, K Neanidis, K Amarantidis, P Dimopoulos, E Chamalidou, ... Cancer chemotherapy and pharmacology 67, 69-73, 2011 | 6 | 2011 |
| Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer L Chelis, N Xenidis, K Amarantidis, P Prassopoulos, E Chamalidou, ... Chemotherapy 56 (5), 353-358, 2010 | 6 | 2010 |
| Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC). L Chelis, S Deftereos, N Xenidis, K Amarantidis, EK Hamalidou, ... Journal of Clinical Oncology 30 (15_suppl), e14567-e14567, 2012 | 5 | 2012 |
